Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Depreciation and Depletion (2018 - 2025)

Historic Depreciation and Depletion for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to $29001.0.

  • BioNexus Gene Lab's Depreciation and Depletion fell 1537.0% to $29001.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $112992.0, marking a year-over-year increase of 1929.43%. This contributed to the annual value of $104160.0 for FY2024, which is 2511.26% up from last year.
  • BioNexus Gene Lab's Depreciation and Depletion amounted to $29001.0 in Q3 2025, which was down 1537.0% from $27800.0 recorded in Q2 2025.
  • BioNexus Gene Lab's Depreciation and Depletion's 5-year high stood at $63129.0 during Q3 2023, with a 5-year trough of -$20879.0 in Q2 2023.
  • Moreover, its 5-year median value for Depreciation and Depletion was $22636.0 (2022), whereas its average is $23871.8.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first surged by 25467.39% in 2021, then plummeted by 19223.8% in 2023.
  • Over the past 5 years, BioNexus Gene Lab's Depreciation and Depletion (Quarter) stood at $22794.0 in 2021, then rose by 8.88% to $24819.0 in 2022, then dropped by 18.99% to $20106.0 in 2023, then soared by 46.97% to $29549.0 in 2024, then decreased by 1.85% to $29001.0 in 2025.
  • Its last three reported values are $29001.0 in Q3 2025, $27800.0 for Q2 2025, and $26642.0 during Q1 2025.